ENTA
Enanta Pharmaceuticals, Inc.
$13.95
+0.12
(+0.87%)
Mkt Cap
323.87M
Volume
136,686
52W Range
5.7-17.15
Sector
Healthcare
Beta
1.01
EPS (TTM)
-2.74
P/E Ratio
-3.12
Revenue (TTM)
69.21M
Rev Growth (5Y)
-11.8%
EPS Growth (5Y)
N/A
Company Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.32M | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.62M | 102.81M | 88.27M | 160.88M | 47.74M |
| Net Income | (81.89M) | (116.05M) | (133.82M) | (121.75M) | (79.00M) | (36.17M) | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M |
| EPS | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 |
| Free Cash Flow | (32.17M) | (96.71M) | (112.21M) | (86.91M) | (70.75M) | 5.64M | 66.00M | 26.24M | 50.15M | 31.07M | N/A | N/A |
| FCF / Share | -1.51 | -4.57 | -5.35 | -4.22 | -3.51 | 0.28 | 3.37 | 1.27 | 2.63 | 1.64 | N/A | N/A |
| Operating CF | (19.27M) | (78.76M) | (103.15M) | (84.78M) | (70.00M) | 7.09M | 71.42M | 29.22M | 52.65M | 35.81M | N/A | N/A |
| Total Assets | 280.73M | 376.65M | 462.27M | 380.59M | 440.86M | 490.79M | 489.83M | 414.23M | 326.64M | 281.28M | N/A | N/A |
| Total Debt | 201.06M | 226.06M | 26.51M | 26.69M | 6.83M | 9.58M | 200,000 | 293,000 | 458,000 | 531,000 | N/A | N/A |
| Cash & Equiv | 32.30M | 37.23M | 85.39M | 43.99M | 57.21M | 87.13M | 51.23M | 63.90M | 65.67M | 16.58M | N/A | N/A |
| Book Value | 64.72M | 128.81M | 216.74M | 321.33M | 399.43M | 455.58M | 462.49M | 393.68M | 301.68M | 269.94M | N/A | N/A |
| Return on Equity | -1.27 | -0.90 | -0.62 | -0.38 | -0.20 | -0.08 | 0.10 | 0.18 | 0.06 | 0.08 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.16M | 18.61M | 15.12M | 18.31M | 14.93M | 16.96M | 14.61M | 17.97M | 17.05M | 18.00M | 18.93M | 18.89M |
| Net Income | (13.09M) | (11.94M) | (18.70M) | (18.25M) | (22.64M) | (22.29M) | (28.82M) | (22.66M) | (31.16M) | (33.41M) | (28.11M) | (39.06M) |
| EPS | -0.45 | -0.56 | -0.87 | -0.86 | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 | -1.58 | -1.33 | -1.86 |
| Free Cash Flow | (7.17M) | (11.84M) | (7.95M) | 17.35M | (16.03M) | (25.55M) | (19.35M) | (21.32M) | (30.27M) | (25.77M) | (22.97M) | (34.28M) |
| FCF / Share | -0.25 | -0.55 | -0.37 | 0.81 | -0.75 | -1.20 | -0.91 | -1.01 | -1.43 | -1.22 | -1.09 | -1.63 |
| Operating CF | (7.16M) | (11.70M) | (6.49M) | 17.51M | (13.49M) | (16.80M) | (10.40M) | (14.78M) | (28.60M) | (24.99M) | (21.60M) | (32.13M) |
| Total Assets | 314.70M | 329.50M | 280.73M | 301.03M | 322.99M | 348.64M | 376.65M | 398.82M | 413.56M | 428.50M | 462.27M | 495.17M |
| Total Debt | 186.62M | 193.18M | 201.06M | 207.10M | 216.14M | 221.29M | 226.06M | 226.17M | 229.86M | 220.00M | 222.44M | 230.80M |
| Cash & Equiv | 34.93M | 37.44M | 32.30M | 44.81M | 60.21M | 84.35M | 37.23M | 35.77M | 63.54M | 39.93M | 85.39M | 95.18M |
| Book Value | 116.59M | 126.59M | 64.72M | 79.28M | 93.54M | 111.82M | 128.81M | 148.91M | 166.11M | 191.88M | 216.74M | 237.82M |
| Return on Equity | -0.11 | -0.09 | -0.29 | -0.23 | -0.24 | -0.20 | -0.22 | -0.15 | -0.19 | -0.17 | -0.13 | -0.16 |
ENTA News
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average – Should You Sell?
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock